{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:49Z","timestamp":1792801969446,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.bulcan.2023.02.023","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T08:16:56Z","timestamp":1688458616000},"page":"1147-1155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Manifestations dysimmunitaires associ\u00e9es aux syndromes my\u00e9lodysplasiques et leuc\u00e9mies my\u00e9lomonocytaires chroniques"],"prefix":"10.1016","volume":"110","author":[{"given":"Vincent","family":"Jachiet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Pierre","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.02.023_bib0290","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.1986.tb07504.x","article-title":"Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies","volume":"63","author":"Mufti","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0295","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1080\/1042819021000016186","article-title":"Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Saif","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0300","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0305","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1\u00a0and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000011","article-title":"Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68\u00a0cases","volume":"93","author":"Mekinian","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0315","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(22)00138-7","article-title":"Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?","volume":"9","author":"Hochman","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0320","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0325","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0330","first-page":"603","article-title":"Risk factors for myelodysplastic syndromes: a case-control study in Greece","volume":"13","author":"Dalamaga","year":"2002","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0335","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamaoncol.2016.6435","article-title":"Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia","volume":"3","author":"Ertz-Archambault","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0340","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.beha.2019.02.002","article-title":"Myeloid disorders after autoimmune disease","volume":"32","author":"Boddu","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0345","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.canep.2014.08.003","article-title":"Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database","volume":"38","author":"Wilson","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0350","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1002\/ajh.24333","article-title":"Autoimmune diseases and myelodysplastic syndromes","volume":"91","author":"Komrokji","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0355","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/39.4.417","article-title":"Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study","volume":"39","author":"Hamidou","year":"2000","journal-title":"Rheumatol Oxf Engl"},{"issue":"9","key":"10.1016\/j.bulcan.2023.02.023_bib0360","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0365","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3\u00a0inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0370","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0375","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0380","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1038\/jid.2015.146","article-title":"Myelodysplasia cutis versus leukemia cutis","volume":"135","author":"Osio","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0385","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bjd.19547","article-title":"Identification of clonal skin myeloid cells by next-generation sequencing in myelodysplasia cutis","volume":"184","author":"Delaleu","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0390","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1080\/10428194.2018.1542152","article-title":"Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review","volume":"60","author":"Wesner","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0395","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.13174","article-title":"Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study","volume":"102","author":"Wesner","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0400","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.semarthrit.2020.07.002","article-title":"Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study","volume":"50","author":"Roupie","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0405","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1002\/art.39790","article-title":"Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142\u00a0patients","volume":"68","author":"Dion","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0410","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00005792-200105000-00003","article-title":"Dermatologic manifestations of relapsing polychondritis. A study of 200\u00a0cases at a single center","volume":"80","author":"Franc\u00e8s","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0415","first-page":"208","article-title":"Myelodysplasia and relapsing polychondritis","volume":"22","author":"Piette","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0420","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ajh.20593","article-title":"Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study","volume":"81","author":"Voulgarelis","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0425","first-page":"701","article-title":"Bone marrow involvement in systemic lupus erythematosus","volume":"110","author":"Chalayer","year":"2017","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0430","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/rheumatology\/kep204","article-title":"Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers","volume":"48","author":"Lofstrom","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0435","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1468-3083.2010.03614.x","article-title":"Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome","volume":"24","author":"Farah","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0440","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1684\/ejd.2016.2812","article-title":"Disseminated granulomatous skin lesions associated with myelodysplastic syndrome treated successfully with tranilast: a case report and review of the literature","volume":"26","author":"Yoneta","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0445","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40257-018-00418-2","article-title":"Neutrophilic dermatoses associated with myeloid malignancies","volume":"20","author":"Lepelletier","year":"2019","journal-title":"Am J Clin. Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0450","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.jid.2019.12.040","article-title":"Next-generation sequencing in myeloid neoplasm-associated sweet's syndrome demonstrates clonal relation between malignant cells and skin-infiltrating neutrophils","volume":"140","author":"Passet","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0455","doi-asserted-by":"crossref","first-page":"715053","DOI":"10.3389\/fimmu.2021.715053","article-title":"Myeloid clonal infiltrate identified with next-generation sequencing in skin lesions associated with myelodysplastic syndromes and chronic myelomonocytic leukemia: a case series","volume":"12","author":"Martin de Fr\u00e9mont","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0460","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2018.07.009","article-title":"Autoimmune diseases in myelodysplastic syndrome favors patients survival: a case control study and literature review","volume":"18","author":"Seguier","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046525","article-title":"Immunohematological findings in myelodysplastic syndrome","volume":"105","author":"Novaretti","year":"2001","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.02.023_bib0470","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2020.272559","article-title":"Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"106","author":"Jachiet","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0475","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/ajh.24618","article-title":"Clinical evolution of autoimmune cytopenias to idiopathic cytopenias\/dysplasias of uncertain significance (ICUS\/IDUS) and bone marrow failure syndromes","volume":"92","author":"Barcellini","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0480","doi-asserted-by":"crossref","first-page":"610019","DOI":"10.3389\/fimmu.2021.610019","article-title":"Somatic mutations and the risk of undifferentiated autoinflammatory disease in MDS: an under-recognized but prognostically important complication","volume":"12","author":"Watad","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0485","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s10620-007-0090-0","article-title":"Concurrent inflammatory bowel disease and myelodysplastic syndrome: report of nine new cases and a review of the literature","volume":"53","author":"Wang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0490","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1183\/09031936.00092910","article-title":"Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan","volume":"37","author":"Ishii","year":"2011","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.023_bib0495","first-page":"1336","article-title":"Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic\/myeloproliferative neoplasms: a French multicentre retrospective case-control study","volume":"40","author":"P\u00e9an de Ponfilly-Sotier","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0500","first-page":"1","article-title":"Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia","author":"Fraison","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0505","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.autrev.2017.07.003","article-title":"Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29\u00a0patients","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0510","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2008.12.011","article-title":"Neutrophilic dermatosis complicating lenalidomide therapy","volume":"61","author":"Thieu","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.02.023_bib0515","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1093\/rheumatology\/keaa696","article-title":"Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report","volume":"60","author":"Corfmat","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","article-title":"Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"43","author":"Fraison","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0525","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0530","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2169\/internalmedicine.46.0291","article-title":"Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Beh\u00e7et's disease by up-front cord blood transplantation","volume":"46","author":"Nonami","year":"2007","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0535","series-title":"Genomic ascertainment for UBA1\u00a0variants and VEXAS syndrome: a population-based study","author":"Beck","year":"2022"},{"issue":"3","key":"10.1016\/j.bulcan.2023.02.023_bib0540","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0545","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59\u00a0cases","author":"Zakine","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0550","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","article-title":"UBA1\u00a0variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome","volume":"157","author":"Zakine","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0555","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-140480","article-title":"Myelodysplasia and bone marrow manifestations of somatic UBA1\u00a0mutated autoinflammatory disease","volume":"136","author":"Obiorah","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0560","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0565","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1\u00a0Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.02.023_bib0285","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","article-title":"Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience","volume":"6","author":"Diarra","year":"2022","journal-title":"Blood Adv"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123002783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:11Z","timestamp":1757792291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123002783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0007455123002783"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.023","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manifestations dysimmunitaires associ\u00e9es aux syndromes my\u00e9lodysplasiques et leuc\u00e9mies my\u00e9lomonocytaires chroniques","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}